Genentech�s Tecentriq improves overall survival as a first-line monotherapy in certain people with advanced non-small cell lung cancer.

Genentech, announced positive data from the Phase III IMpower110 study evaluating Tecentriq (atezolizumab) as a first-line (initial) monotherapy compared with cisplatin or carboplatin and pemetrexed or gemcitabine (chemotherapy) in advanced non-squamous and squamous non-small cell lung cancer (NSCLC) without ALK or EGFR mutations (wild-type; WT).

The study met its primary endpoint in an interim analysis showing that Tecentriq monotherapy improved overall survival (OS) by 7.1 months compared with chemotherapy alone (median OS=20.2 versus 13.1 months; hazard ratio [HR]=0.595, 95% CI: 0.398�0.890; p=0.0106) in people with high PD-L1 expression (TC3/IC3-WT). Encouraging OS (18.2 versus 14.9 months; HR=0.717, 95% CI: 0.520�0.989) was also observed in people with medium levels of PD-L1 expression (TC2/3 or IC2/3-WT), however these data did not reach statistical significance at this interim analysis. The study will continue to final analysis for people with lower levels of PD-L1 expression. Safety for Tecentriq appeared to be consistent with its known safety profile, and no new safety signals were identified.